Related Experiment Videos
Second-line chemotherapy for non-small cell lung cancer: is more better or just simply more?
Lung Cancer (Amsterdam, Netherlands)
|May 16, 2002
Abstract
No abstract available in PubMed .
Related Concept Videos
Articles linked to this work by shared authors, journal, and citation graph.
Adjuvant Osimertinib in Resected EGFR-Mutated Stage IB-IIIA Non-Small Cell Lung Cancer: Exploratory 8-year Overall Survival Landmark Update from the ADAURA Trial [161/175].
Journal of thoracic oncology : official publication of the International Association for the Study of Lung Cancer·2026
Biomarker Testing Among Patients With Nonsquamous NSCLC Across Three Time Periods and Three Testing Platforms-A Brief Report.
JTO clinical and research reports·2026
Evaluating eight smoking metrics for modelling survival in non-small cell lung cancer.
Cancer epidemiology·2026
Patient-Reported Outcomes in FLAURA2: Osimertinib with or without Chemotherapy in Patients with Previously Untreated EGFR-Mutated Advanced Non-Small Cell Lung Cancer.
Clinical cancer research : an official journal of the American Association for Cancer Research·2026
Weight, BSA, Toxicity, and Efficacy of Tyrosine Kinase Inhibitors for ALK-Mutated NSCLC.
JTO clinical and research reports·2026
Discordance in pleural mesothelioma response classification and modelling of impact on clinical trials.
Lung cancer (Amsterdam, Netherlands)·2026
Reassessing surgical resection in small cell lung cancer in the multimodal treatment era.
Lung cancer (Amsterdam, Netherlands)·2026
Characterization of the genomic and transcriptomic landscape of invasive non-mucinous lung adenocarcinoma based on IASLC grading.
Lung cancer (Amsterdam, Netherlands)·2026
Molecular concordance and clonal dynamics of KRAS mutations in lung adenocarcinoma across distinct clinical scenarios.
Lung cancer (Amsterdam, Netherlands)·2026
Long-term safety of first-line osimertinib plus platinum-pemetrexed in EGFR-mutated advanced NSCLC: FLAURA2.
Lung cancer (Amsterdam, Netherlands)·2026
The efficacy and feasibility of neoadjuvant immunochemotherapy versus chemotherapy in Limited-Stage Small-Cell lung cancer.
Lung cancer (Amsterdam, Netherlands)·2026